#ASCO26: Cancer immunotherapy's magic bullet era is fading. Here's what's next
The two best-selling checkpoint inhibitors — Merck’s Keytruda and Bristol Myers Squibb’s Opdivo — are now approaching their patent cliffs. And the biopharma ind...
The two best-selling checkpoint inhibitors — Merck’s Keytruda and Bristol Myers Squibb’s Opdivo — are now approaching their patent cliffs. And the biopharma industry is coming to terms with the fact that it may not be able ...